Impact of Postoperative Chemotherapy on Survival in Patients with Primary Central Nervous System Lymphoma: A Study Based on the SEER Database

被引:0
作者
Chen, Yushan [1 ,2 ]
Zheng, Shuishun [3 ]
Zheng, Shunyong [1 ]
Lin, Hong [3 ]
Wei, Lizhen [1 ]
Chen, Shaoqiang [4 ]
机构
[1] Zhangzhou Hosp, Imaging Dept, Zhangzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Imaging Dept, Zhangzhou Affiliated Hosp, Zhangzhou, Fujian, Peoples R China
[3] Zhangzhou Hosp, Neurosurg Dept, Zhangzhou, Fujian, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Fujian, Peoples R China
关键词
postoperative chemotherapy; overall survival; primary central nervous system lymphoma; SEER; HIGH-DOSE METHOTREXATE; PRIMARY CNS LYMPHOMA; MALIGNANT-LYMPHOMA; PROGNOSTIC MODEL; EPIDEMIOLOGY; SURVEILLANCE; MANAGEMENT; RITUXIMAB; DIAGNOSIS; THERAPY;
D O I
10.12968/hmed.2024.0243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Background We aimed to investigate the impact of postoperative chemotherapy (POCT) on survival in patients with primary central nervous system lymphoma (PCNSL) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods This study included 786 PCNSL patients, of which 605 received chemotherapy after surgery, and 181 did not. Data from the SEER registry database (2007-2020) were used to analyze PCNSL. Baseline information, including age, sex, race, marital status, primary tumour site, histological type, summary stage, surgical procedures, chemotherapy, and radiotherapy, was analyzed. Propensity Score Matching (PSM) (1:1) was employed to balance the effects of confounding variables between the two groups. Subsequently, Cox regression and bidirectional stepwise regression were used to identify independent prognostic factors. Kaplan-Meier (K-M) survival curves were constructed to assess the impact of POCT on patient prognosis. Additionally, two cases of PCNSL with typical magnetic resonance imaging appearances were presented. Results Multivariate Cox regression results revealed that age older than 60 years (hazard ratio [HR] = 1.786; 95% confidence interval [CI]: 1.272-2.509; p = 0.001) and absence of POCT (HR = 2.841; 95% CI: 2.159-3.738; p < 0.001) were independent prognostic risk factors, while primary tumour locations in the meninges (HR = 0.136; 95% CI: 0.032-0.569; p = 0.006) and other nervous system regions (HR = 0.552; 95% CI: 0.326-0.936; p = 0.027), as well as histological morphologies such as diffuse large B-cell lymphoma (HR = 0.233; 95% CI: 0.128-0.425; p < 0.001) and non-Hodgkin lymphoma (HR = 0.559; 95% CI: 0.356-0.876; p = 0.011), were associated with favourable patient outcomes. K-M curves demonstrated that the group undergoing POCT had a significantly more favourable prognosis compared to the non-POCT group, before (HR = 0.454; 95% CI: 0.343-0.600; p < 0.0001) or after PSM (HR = 0.580; 95% CI: 0.431-0.780; p < 0.0001). For patients with PCNSL, those with tumours located in the infratentorial region (HR = 0.231; 95% CI: 0.078-0.682; p = 0.046), supratentorial region (HR = 0.250; 95% CI: 0.163-0.383; p < 0.0001), overlapping brain regions (HR = 0.201; 95% CI: 0.056-0.727; p = 0.0058), and those who underwent biopsy (HR = 0.740; 95% CI: 0.463-1.182; p = 0.003), subtotal resection (STR) (HR = 0.490; 95% CI: 0.265-0.906; p = 0.0064), or gross total resection (GTR) (HR = 0.613; 95% CI: 0.292-1.287; p = 0.0003) had better prognoses in the postoperative chemotherapy group compared to the non-chemotherapy group. Conclusion POCT significantly improves the prognosis of PCNSL patients and identifies the characteristics of the benefiting population. This information aids clinical practitioners in designing personalized treatment plans for individuals and advancing precise treatment.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Primary central nervous system lymphoma
    Loew, Sarah
    Han, Catherine H.
    Batchelor, Tracy T.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [32] Primary central nervous system lymphoma
    Batchelor, Tracy T.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 379 - 385
  • [33] Primary central nervous system lymphoma
    Gelabert-Gonzalez, M.
    Castro Bouzas, D.
    Serramito-Garcia, R.
    Frieiro Dantas, C.
    Aran Echabe, E.
    NEUROLOGIA, 2013, 28 (05): : 283 - 293
  • [34] Primary central nervous system lymphoma
    Citterio, Giovanni
    Reni, Michele
    Gatta, Gemma
    Ferreri, Andres Jose Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 113 : 97 - 110
  • [35] Primary Central Nervous System Lymphoma
    Gallop-Evans, E.
    CLINICAL ONCOLOGY, 2012, 24 (05) : 329 - 338
  • [36] Primary Central Nervous System Lymphoma
    Gerstner, Elizabeth R.
    Batchelor, Tracy T.
    ARCHIVES OF NEUROLOGY, 2010, 67 (03) : 291 - 297
  • [37] Primary central nervous system lymphoma
    AlShomar, Ahmad
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2024, 49 (03) : 209 - 215
  • [38] A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime
    Bairey, Osnat
    Lebel, Eyal
    Buxbaum, Chen
    Porges, Tzvika
    Taliansky, Alisa
    Gurion, Ronit
    Goldschmidt, Neta
    Shina, Tzahala Tzuk
    Zektser, Miri
    Hofstetter, Liron
    Siegal, Tali
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (05) : 838 - 847
  • [39] Primary central nervous system lymphoma: Inter-compartmental progression
    Raval, Vishal
    Binkley, Elaine
    Aronow, Mary E.
    Valenzuela, Juan
    Peereboom, David M.
    Wei, Wei
    Srivastava, Sunil
    Davanzo, Jaqueline
    Boldt, Herbert Culver
    McGarrey, Mark P.
    Papaliodis, George N.
    Sobrin, Lucia
    Kim, Ivana K.
    Vavvas, Dimitrios G.
    Eliott, Dean
    Nayak, Lakshmi
    Dodds, Emilio
    del Pont, Francisco Marco
    Singh, Arun D.
    EJHAEM, 2022, 3 (02): : 362 - 370
  • [40] The Role of Rituximab in Primary Central Nervous System Lymphoma
    Bromberg, Jacoline E. C.
    van der Meulen, Matthijs
    Doorduijn, Jeanette K.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (08)